close up of a beautiful dragonfly
Biotech

AbbVie halts development of Dragonfly cancer asset in midflight

AbbVie has terminated a phase 1 trial of the natural killer-cell engager ABBV-303, licensed from Dragonfly as part of an ongoing partnership.
Darren Incorvaia Oct 29, 2025 1:47pm
GeminiGeneratedImagewmbtpzwmbtpzwmbtpng

First FDA IND Milestone Using Human Vascularized Organoid Data

Oct 27, 2025 8:00am
theatre stage with red curtains

Novartis’ phase 3 wins in Sjögren's see high placebo effect

Oct 29, 2025 12:03pm
GettyImages-1494029118jpg

iRegene's Scalable Tech Unlocks Commercial Cell Therapies

Oct 27, 2025 8:00am
GSK ESMO

GSK loses hope for CD226 cancer therapies, dropping ph. 2 assets

Oct 29, 2025 6:29am
De-Risking Clinical Development Strategic Multipliers in Global Trials

De-Risking Clinical Development: Strategic Multipliers in Global Trials

Oct 27, 2025 8:00am
More News

Regeneron pledges $1B+ for ModeX multispecific antibodies

Oct 29, 2025 11:04am

Kyverna links CAR-T to autoimmune improvements in small trial

Oct 29, 2025 10:00am

Roche's Flatiron Health debuts 6 new blood cancer data sets

Oct 29, 2025 9:00am

BridgeBio's calcium deficiency candidate scores phase 3 win

Oct 29, 2025 7:00am